Where Will NRX Pharmaceuticals Inc (NRXP) Stock Go Next After It Is Up 24.00% in a Week?

Overall market sentiment has been high on NRX Pharmaceuticals Inc (NRXP) stock lately. NRXP receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

NRX Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NRXP!

See Full NRXP Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With NRXP Stock Today?

NRX Pharmaceuticals Inc (NRXP) stock is trading at $1.24 as of 10:39 AM on Friday, Nov 18, a rise of $0.02, or 1.75% from the previous closing price of $1.22. The stock has traded between $1.18 and $1.34 so far today. Volume today is more active than usual. So far 417,111 shares have traded compared to average volume of 270,937 shares. To screen for more stocks like NRX Pharmaceuticals Inc click here.

More About NRX Pharmaceuticals Inc

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. Click Here to get the full Stock Report for NRX Pharmaceuticals Inc stock.